by Physician’s Briefing Staff In a recent trial, a new melanoma vaccine, mRNA-4157 (V940), when taken in combination with Keytruda (pembrolizumab), was found to be effective in battling the deadly skin cancer. People with advanced melanomas who received the vaccine plus Merck’s cancer drug Keytruda were 49 percent less likely to die or have their...